Horner has more than 40 years of industry experience gained with biotech and big pharma companies. He was most recently ceo of Prestwick Pharmaceuticals, a private CNS company that was sold to Biovail Corporation and Ovation Pharmaceuticals in 2008.
Prior to joining Prestwick, Horner was ceo of Vicuron, a publicly listed anti-infectives company that was sold to Pfizer for US$1.9bn in 2005. He also worked for Ligand Pharmaceuticals following a career at Abbott Laboratories where rose to president of the company’s business in Canada.
‘I have been attracted to this opportunity by the company’s rich pipeline of clinical and pre-clinical drug candidates focused on dermatological indications, its deep understanding of the science behind a number of serious skin disorders, as well as its technology platform with broad utility. I am sure that from this strong base we will be able to generate significant value for Creabilis shareholders,’ said Horner.
Dermatology specialist appoints chairman
George Horner joins Creabilis of Luxembourg
You may also like
Regulatory
![Early phase analytical strategy for biosimilars in a shifting regulatory landscape]()
Early phase analytical strategy for biosimilars in a shifting regulatory landscape
As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Pharmaceutical
![Formulation freedom in clinical development: Why Fill2Weight matters]()
Formulation freedom in clinical development: Why Fill2Weight matters
As drug discovery accelerates, especially for poorly soluble small‑molecule compounds, formulation teams increasingly modify particle size, morphology and structure to improve dissolution in the body. This is precisely where 3P innovation’s proprietary Fill2Weight Gravimetric Powder Filler becomes a game‑changer
Research & Development
![Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline]()
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline
The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period
Pharmaceutical
![Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate]()
Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate
The agreement will expand Teva’s biosimilars pipeline, with the company securing exclusive commercialisation rights for Polpharma Biologics’ proposed ocrelizumab biosimilar across key global markets
Pharmaceutical
![Pouching solutions for sterile and moisture-sensitive devices]()
Pouching solutions for sterile and moisture-sensitive devices
Sterile pouch loading and sealing is far more complex than a conventional packaging operation: When the pouch itself becomes the primary sterile barrier (and the product is filled aseptically) the packaging process must be engineered with the same level of care as the filling operation itself